socalTECH

MAY 30, 2017

San Diego-based Arcturus Therapeutics , a developer of mRNA-based treatments for disease, has signed a deal to receive up to $3M in funding from the Cystic Fibrosis Foundation Therapeutics, a nonprofit which supports drug discovery and development. READ MORE>>.

Arcturus 167

Arcturus San Diego Develop Development 167

L.A. Business Journal

MAY 17, 2021

Augmented reality and holographic technology exist largely as a novelty for most Americans. But as smartphone cameras evolve and 5G networks come online, many investors and businesses are betting that the technology will become commonplace.

Arcturus 223

Arcturus Software Networking Technology 223

socalTECH

JUNE 11, 2015

San Diego-based RNA therapeutics developer Arcturus Therapeutics announced this morning that it is in a strategic collaboration deal, with Johnson & Johnson Innovation. Plus, Janssen will assume responsibility for development and commercialization costs associated with the new program. READ MORE>>.

Arcturus 100

Arcturus San Diego Sales Platform 100

socalTECH

MAY 16, 2011

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. Arcturus first invested in Pliant in 2007. SanDisk is a major manufacturer of flash memory.

Arcturus 150

Arcturus Pasadena Venture Capital Equity 150

Xconomy

OCTOBER 23, 2017

Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.

Arcturus 65

Arcturus San Diego Research Develop 65

Xconomy

MAY 30, 2017

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.

Arcturus 65

Arcturus San Diego Research Funding 65

socalTECH

JANUARY 15, 2010

Moser is a native of Switzerland, and will remain as Chief Technology Officer at the firm. ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others. Christophe Moser, who is moving to Switzerland to become Professor of Engineering and Industrial Relations at Ecole Polytechnique Federale de Lausanne (EPFL).

Arcturus 124

Arcturus Chief Technology Officer Monrovia Equity 124